Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.47 |
| ▸ | GALR3 | O60755 | 1/20 | 0.41 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | SCN4A | P35499 | 1/20 | 0.38 |
| ▸ | TYR | P14679 | 1/20 | 0.37 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 3/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10058352 | 0.85 | KIF11 (0.40) | IRAK4GALR3NR2F2SMN1; SMN2LMNA | |
| SCHEMBL17562165 | 0.81 | IRAK4 (0.47) | IRAK4GALR3NR2F2SMN1; SMN2LMNA | |
| SCHEMBL2600744 | 0.81 | HTT (0.47) | IRAK4SMN1; SMN2LMNAHTTNPC1 | |
| SCHEMBL30926459 | 0.80 | HTT (0.61) | SMN1; SMN2LMNAHTTNPC1MAPT | |
| SCHEMBL20609574 | 0.80 | USP10 (0.45) | GALR3NR2F2SMN1; SMN2LMNAHTT | |
| SCHEMBL682225 | 0.80 | MAP4K4 (0.51) | IRAK4 | |
| SCHEMBL26238011 | 0.80 | HTT (0.42) | GALR3NR2F2SMN1; SMN2LMNAHTT | |
| SCHEMBL12141871 | 0.80 | CSF1R (0.48) | NR2F2HTTPDE1BEGFR | |
| SCHEMBL14566483 | 0.80 | IRAK4 (0.46) | IRAK4GALR3NR2F2SMN1; SMN2LMNA | |
| SCHEMBL24139924 | 0.77 | IRAK4 (0.44) | IRAK4GALR3NR2F2SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022098992-A1 | USE OF MACROCYCLIC COMPOUNDS IN METHODS OF TREATING CANCER | SCORPION THERAPEUTICS, INC. (US) | 2022-05-12 | — | — | WO | disclosed |
| EP-2710018-B1 | MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | FUNDACION CENTRO NAC DE INVESTIGACIONES ONCOLOGICAS CARLOS III (ES) | 2021-12-29 | — | — | EP | disclosed |
| US-10335409-B2 | Inhibitors of hepatitis C virus | GILEAD PHARMASSET LLC (US) | 2019-07-02 | — | — | US | disclosed |
| WO-2019079357-A1 | TNIK MODULATORS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. (US) | 2019-04-25 | — | — | WO | disclosed |
| US-9808466-B2 | Macrocyclic compounds as protein kinase inhibitors | FUNDACIÓN CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III | 2017-11-07 | — | — | US | disclosed |
| US-20170290827-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2017-10-12 | — | — | US | disclosed |
| US-20160296528-A1 | MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) (ES) | 2016-10-13 | — | — | US | disclosed |
| US-9296782-B2 | Inhibitors of hepatitis C virus | GILEAD SCIENCES, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-9284334-B2 | Macrocyclic compounds as protein kinase inhibitors | FUNDACIÓN CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III (ES) | 2016-03-15 | — | — | US | disclosed |
| US-20150175655-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2015-06-25 | — | — | US | disclosed |
| US-20140256717-A1 | MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) | 2014-09-11 | — | — | US | disclosed |
| US-20140017198-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2014-01-16 | — | — | US | disclosed |
| US-8349857-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2013-01-08 | — | — | US | disclosed |
| US-8202879-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2012-06-19 | — | — | US | disclosed |
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | SHIONOGI & CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
| US-20070191380-A1 | KINASE INHIBITOR SCAFFOLDS AND METHODS FOR THEIR PREPARATION | IRM LLC (BM) | 2007-08-16 | — | — | US | disclosed |
| US-7176312-B2 | Kinase inhibitor scaffolds and methods for their preparation | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | ERBB2, EGFR, ABL1 | IRAK4 1421/4885GALR3 606/4885NR2F2 683/4885 |
| US-20150175655-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, GOT1 | IRAK4 3610/4885GALR3 4227/4885NR2F2 2776/4885 |
| US-20140256717-A1 | MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | PIM1, PIM3, PIM2 | IRAK4 296/4885GALR3 3454/4885NR2F2 3663/4885 |
| US-20170290827-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, GOT1 | IRAK4 3766/4885GALR3 4140/4885NR2F2 2714/4885 |
| US-20160296528-A1 | MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | PIM1, PIM3, PIM2 | IRAK4 296/4885GALR3 3454/4885NR2F2 3663/4885 |
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | ERBB2, EGFR, ABL1 | IRAK4 1421/4885GALR3 606/4885NR2F2 683/4885 |
| US-20070191380-A1 | KINASE INHIBITOR SCAFFOLDS AND METHODS FOR THEIR PREPARATION | MAP2K2, MAP2K1, MAP2K7 | IRAK4 630/4885GALR3 2284/4885NR2F2 2369/4885 |
| US-10335409-B2 | Inhibitors of hepatitis C virus | HAVCR2, SLC10A1, GOT1 | IRAK4 3766/4885GALR3 4140/4885NR2F2 2714/4885 |
| US-20140017198-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, GOT1 | IRAK4 3766/4885GALR3 4140/4885NR2F2 2714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.